Glooko and Diasend Merge to Deliver the World’s Premier Diabetes Management Platform.
The combined business enables implementation in 4000 health systems for diabetes in 23 countries and 15 languages. Which affects tens of millions of people with diabetes.
For people either living with or caring for people with diabetes, Glooko and Diasend are well-known for making diabetes management easier by offering best-in-class diabetes management and analytics platforms that facilitate data driven care for patients and clinicians. In a move that will accelerate the overarching mission to make diabetes management easier worldwide, Glooko and Diasend today announced they will merge into a unified company.
“This is a big day for us – we are thrilled to come together to be able to deliver products and services that will offer even more value to patients and healthcare providers around the world”, says Rick Altinger, CEO of Glooko, Inc.
“This is without a doubt the best possible scenario for our two companies, as well as for patients and the care teams that serve them. From our standpoint, this means adding even more functionality to an already very strong technical platform,” says Anders Sonesson, CEO of Diasend AB.
”Since the start in 2004, Diasend has been an exciting and interesting company in our portfolio, says Ingvar Andersson, Head of Investments at Chalmers Ventures. I have followed its development closely. Now the company takes a giant step further with Glooko providing many new development opportunities ahead.”
The two companies, which have chosen to unite under the Glooko name, have recently raised $8M in equity financing, led by global venture capital firm Canaan Partners, to accelerate integration and sales efforts. Other investors include Social Capital, Samsung Ventures and Yogen Dalal, Glooko’s founder and partner emeritus at venture capital firm Mayfield fund.